Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma

Trial Profile

Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary) ; Itraconazole
  • Indications Allergic bronchopulmonary aspergillosis; Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Pulmatrix
  • Most Recent Events

    • 23 Aug 2023 According to a Pulmatrix media release, data assessing drug-drug Interactions with inhaled itraconazole using pharmacokinetic Modelling, based on data from this trial were published in the peer-reviewed American Association of Pharmaceutical Scientists (AAPS) Journal.
    • 23 Aug 2023 Results presented in the Pulmatrix Media Release.
    • 06 Nov 2019 Results assessing safety, tolerability and pharmacokinetics of PUR1900 in healthy volunteers and patients with Asthma published in the British Journal of Clinical Pharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top